SCHEMBL21696322

SCHEMBL21696322

Cc1cccc(C(C)C2=CNC3SC3N2)c1C

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 4/20 0.42
▸ ADRA2B P18089 4/20 0.42
▸ ADRA2C P18825 4/20 0.42
▸ ADRA1A P35348 3/20 0.42
▸ ADRA1B P35368 3/20 0.42
▸ ADRA1D P25100 2/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ SLC6A2 P23975 1/20 0.41
▸ HTR7 P34969 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27639614 0.75 ADRA2A (0.41) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL1053969 0.69 TSHR (0.55) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL4260014 0.67 ADRA2A (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL28239409 0.67 ADRA2A (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13218794 0.65 ADRA2A (0.42) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL14439671 0.65 ADRA2A (0.42) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13218812 0.65 ADRA2A (0.42) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL10487817 0.64 ADRA2A (0.50) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL19203397 0.64 TSHR (0.46) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL196657 0.63 TSHR (0.50) ADRA2AADRA2BADRA2CADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3656374-A1 OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES ALLERGAN, INC. (US) 2020-05-27 — — EP disclosed
EP-1879553-B1 OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES ALLERGAN INC (US) 2020-02-12 — — EP disclosed
Send feedback